Form 8-K - Current report:
SEC Accession No. 0001999371-25-001293
Filing Date
2025-02-07
Accepted
2025-02-07 08:52:48
Documents
14
Period of Report
2025-02-07
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tnxp-8k_020725.htm   iXBRL 8-K 26531
2 PRESS RELEASE ex99-01.htm EX-99.01 32318
  Complete submission text file 0001999371-25-001293.txt   241125

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tnxp-20250207.xsd EX-101.SCH 2991
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tnxp-20250207_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tnxp-20250207_pre.xml EX-101.PRE 24149
16 EXTRACTED XBRL INSTANCE DOCUMENT tnxp-8k_020725_htm.xml XML 3543
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 25599465
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)